Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?
Rheumatology International · 2023
DOI: 10.1007/s00296-023-05320-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology International, 2023. Verfasst von Zehra Ozsoy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. dr.zehraduman@hotmail.com. Hauptthemen laut MEDLINE: Tuberculosis, Latent Tuberculosis, Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
We aimed to obtain the effects of immunosuppressive doses on the QuantiFERON-TB Gold Plus (QFT-Plus) test results in Rheumatoid Arthritis (RA) patients. Besides this, the impact of the TB2 tube in QFT-Plus test was also investigated. This study included RA patients registered to HURBIO and were screened via QFT-Plus test for latent tuberculosis between January 2018 and March 2021, before the initiation of treatment of biologic/targeted-synthetic disease modifying anti-rheumatismal drugs (b/ts-DMARDs). Patients using methotrexate ≥ 10 mg or leflunomide (any dose) or steroids (≥ 7.5 mg prednisolone) at the time of QFT-Plus test were classified as the "high dose" group and the rest of the patients constituted the "low dose" group. The study included 534 RA patients; 353 [66.1%] in the high-dose group and 181 [33.9%] in the low-dose group. While QFT-Plus test was positive in 10.5% (37/353) patients in the high-dose group, it was positive in 20.4% (37/181) patients in the low-dose group (p < 0.001). The percentage of QFT-Plus indeterminate results were similar (around 2%) in both groups. The contribution of the TB2 tube to QFT-Plus test positivity was 6.89%. During a median (inter-quartile range) follow-up period of 23 (7-38) months under treatment of b/ts-DMARDs, latent TB reactivation was not observed. Primer active tuberculosis disease developed in two patients. Positive test results of Interferon-Gamma Release Assays (IGRAs) could decrease as immunosuppressive treatment doses increase in patients with RA and addition of the TB2 tube could increase test sensitivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. dr.zehraduman@hotmail.com.
- Department of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
ORCID-Profile: Zehra Ozsoy
Zitieren
APA
Ozsoy, Z., Ozdemir, A., Ekici, M., Bilgin, E., Kılıc, L., Kiraz, S., Sarıbas, Z., Sener, B., & Karadag, O. (2023). Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?. Rheumatology International. https://doi.org/10.1007/s00296-023-05320-7
Vancouver
Ozsoy Z, Ozdemir A, Ekici M, Bilgin E, Kılıc L, Kiraz S, et al. Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?. Rheumatology International. 2023. doi:10.1007/s00296-023-05320-7
BibTeX
@article{Ozsoy2023,
author = {Ozsoy, Zehra and Ozdemir, Adem and Ekici, Mustafa and Bilgin, Emre and Kılıc, Levent and Kiraz, Sedat and Sarıbas, Zeynep and Sener, Burçin and Karadag, Omer},
title = {Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?},
journal = {Rheumatology International},
year = {2023},
doi = {10.1007/s00296-023-05320-7}
}
EUVIMED